Elevance Health, Inc.

Elevance Health, Inc. officers expect to speak with investors and analysts this week, reaffirming the company's full-year 2026 shareholders' earnings guidance. The company expects at least $19.85 per diluted share, including approximately $6.90 per diluted share of net unfavorable items. Excluding these items, adjusted shareholders' earnings are anticipated to be at least $26.75 per diluted share. Additionally, the full-year 2026 benefit expense ratio guidance of 90.2% plus or minus 50 basis points was reaffirmed.

Elevance Health, Inc. has filed its Quarterly Report on Form 10-Q for the period ended March 31, 2026. The filing includes the company's unaudited consolidated financial statements, covering balance sheets, income statements, and cash flows. As of April 15, 2026, the company reported 217,162,380 shares of common stock outstanding.

Elevance Health reported first-quarter 2026 results exceeding expectations, with operating revenue reaching $49.5 billion, a 1.5% increase year-over-year. The company raised its full-year 2026 adjusted diluted EPS guidance to at least $26.75, citing underlying business strength and improved visibility. Despite a $935 million accrual for a CMS matter, strong operating cash flow and capital returns to shareholders underscore a positive outlook.